ScripRegenxbio Inc. thinks it could grab a sizable portion of a crowded market for retinal diseases that stands to grow significantly over the next several years with interim Phase II data showing relativ
Pink SheetNTLA-2002 and 4D-150, which are single-dose, gene therapy candidates for hereditary angioedema and neovascular age-related macular degeneration (wet AMD) respectively, are among the latest products to